Gemfibrozil Therapy

Introduction to Gemfibrozil

Gemfibrozil is primarily indicated for treating severe hypertriglyceridemia (>500 mg/dL) to reduce the risk of pancreatitis, and as a second-line agent for raising HDL cholesterol levels in patients with low HDL and elevated triglycerides when statins are not tolerated 1

The American Diabetes Association recommends lifestyle modifications and glycemic control as first-line approaches for patients with hypertriglyceridemia, with gemfibrozil considered for those with triglycerides >500 mg/dL 3, 1
Gemfibrozil 600 mg twice daily is indicated to reduce the risk of pancreatitis in patients with triglycerides >500 mg/dL 3, 1
For patients with triglycerides 200-500 mg/dL, statins are first-line if LDL is also elevated, while gemfibrozil is an alternative when statins are not tolerated 4, 1

Gemfibrozil decreases triglycerides by approximately 50-54% 1
Gemfibrozil increases HDL cholesterol by 23-36% 1
The American Heart Association suggests gemfibrozil for patients with known coronary artery disease and low HDL cholesterol, especially when combined with elevated triglycerides 2
Gemfibrozil may be considered in patients with LDL cholesterol between 100-129 mg/dL and HDL <40 mg/dL who are statin-intolerant 4

The American College of Cardiology warns of increased risk of myositis and rhabdomyolysis with gemfibrozil-statin combinations, particularly in patients with renal insufficiency 4
Fenofibrate may be safer than gemfibrozil when combined with statins due to lower risk of myositis 4

Baseline lipid panel, liver function tests, and creatine kinase are recommended before initiating gemfibrozil therapy 6
Follow-up lipid panel is recommended 4-12 weeks after initiation of gemfibrozil 6
Monitoring for clinical evidence of myopathy is necessary, especially when combined with statins 4

Gemfibrozil can be effective in diabetic patients with marked hypertriglyceridemia, but improved glycemic control should be the first priority before adding gemfibrozil 3, 1
Gemfibrozil (600 mg twice daily) can reduce triglyceride levels by approximately 18% in HIV patients with hypertriglyceridemia 5